Michael T. Scerba

TL;DR: The role of neuro inflammation in neurodegenerative diseases is evaluated, focusing specifically on the role of TNF-α in neuroinflammation, as well as appraise current research on the potential of IMiDs as treatments for neurological disorders.

TL;DR: The efficacy of thalidomides and the more potent derivative 3,6′‐dithiothalidomide on dyskinesia was tested in the 6‐hydroxydopamine Parkinson's disease model.

TL;DR: Complementary animal and cellular studies demonstrated DP and Pom mediated reductions in markers of neuroinflammation and α-synuclein-induced toxicity, leading to an amelioration of behavioral deficits with DP providing greater efficacy.

TL;DR: The therapeutic potential of 3,6′-DT is explored in an animal model of moderate TBI using Sprague-Dawley rats subjected to controlled cortical impact to represent a potential therapy to ameliorate TBI-induced functional deficits.

TL;DR: The role of neuroinflammation is summarized in psychiatric disorders such as major depressive disorder, generalized anxiety disorder, post-traumatic stress disorder, and bipolar disorder, as well as in neurodegenerative disorders, and current research on the potential of immunomodulatory imide drugs (IMiDs) as a new treatment strategy for these disorders are introduced.